{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:14Z","timestamp":1787698454483,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01358-x","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:41:40Z","timestamp":1764841300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant Immune Checkpoint Inhibition in MSI-H\/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9811-7754","authenticated-orcid":false,"given":"Wajahat","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehak Ejaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishbah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Moeen-Ud-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi Mohammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Dadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"13","key":"1358_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. 2022;17(13):795972.","journal-title":"Front Immunol"},{"issue":"9","key":"1358_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","volume":"73","author":"Z Wang","year":"2024","unstructured":"Wang Z, Cheng S, Yao Y, Liu S, Liu Z, Liu N, et al. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR\/MSI-H colorectal and gastric cancers. Cancer Immunol Immunother. 2024;73(9):182.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"1358_CR3","doi-asserted-by":"publisher","first-page":"e2110","DOI":"10.1002\/onco.13955","volume":"26","author":"J Trojan","year":"2021","unstructured":"Trojan J, Stintzing S, Haase O, Koch C, Ziegler P, Demes M, et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H\/dMMR rectal cancer. Oncologist. 2021;26(12):e2110\u20134.","journal-title":"Oncologist"},{"issue":"27","key":"1358_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466497","volume":"15","author":"Z Deng","year":"2024","unstructured":"Deng Z, Luo Y, Chen X, Pan T, Rui Y, Hu H, et al. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR\/MSI-H locally advanced colorectal cancer. Front Immunol. 2024;15(27):1466497.","journal-title":"Front Immunol"},{"issue":"12","key":"1358_CR5","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","volume":"9","author":"OE Emiloju","year":"2023","unstructured":"Emiloju OE, Sinicrope FA. Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review. JAMA Oncol. 2023;9(12):1708\u201315.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1358_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/OP.22.00762","volume":"19","author":"IH Sahin","year":"2023","unstructured":"Sahin IH, Zhang J, Saridogan T, Gorantla V, Rhree J, Malhotra M, et al. Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future. JCO Oncol Pract. 2023;19(5):251\u20139.","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"1358_CR7","doi-asserted-by":"publisher","first-page":"1182299","DOI":"10.3389\/fimmu.2023.1182299","volume":"27","author":"R Yang","year":"2023","unstructured":"Yang R, Wu T, Yu J, Cai X, Li G, Li X, et al. Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study. Front Immunol. 2023;27(14):1182299.","journal-title":"Front Immunol"},{"issue":"25","key":"1358_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913483","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yang R, Wu T, Cai X, Li G, Yu K, et al. Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR\/MSI\u2043H locally advanced colorectal cancer: a single-center real-world study. Front Immunol. 2022;13(25):913483.","journal-title":"Front Immunol"},{"key":"1358_CR9","doi-asserted-by":"crossref","unstructured":"Zhang Q, Li J, Shen L, Li Y, Wang X. Opportunities and challenges of immunotherapy for dMMR\/MSI-H colorectal cancer. Cancer Biology & Medicine. 2023;","DOI":"10.20892\/j.issn.2095-3941.2023.0240"},{"issue":"6","key":"1358_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1120684","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y, et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions? Front Immunol. 2023;14(6):1120684.","journal-title":"Front Immunol"},{"issue":"4","key":"1358_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AGJ, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-deficient early-stage colon cancer. Nat Med. 2020;26(4):566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"issue":"21","key":"1358_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"issue":"23","key":"1358_CR13","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish MA, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(23):2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"issue":"6","key":"1358_CR14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability\u2013high locally advanced rectal cancer. Clin Cancer Res. 2022;28(6):1136\u201346.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1358_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PG de Gooyer","year":"2024","unstructured":"de Gooyer PG, Verschoor YL, Bloemendal HJ, van den Berg JG, Goffin EG, Wouters MW, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer (NICHE-3). Nat Med. 2024;30(4):878\u201386. https:\/\/doi.org\/10.1038\/s41591-024-03250-w.","journal-title":"Nat Med"},{"issue":"1","key":"1358_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. The Lancet Gastroenterology & Hepatology. 2022;7(1):38\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(21)00348-4.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"12","key":"1358_CR17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, Raghav KP, Murphy MB, Fleming ND, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41(12):2181\u201390. https:\/\/doi.org\/10.1200\/JCO.22.01351.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1358_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016646","volume":"13","author":"J Shan","year":"2022","unstructured":"Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13(27):1016646.","journal-title":"Front Immunol"},{"issue":"7","key":"1358_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","volume":"25","author":"JH Yu","year":"2024","unstructured":"Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, et al. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study. Lancet Oncol. 2024;25(7):843. https:\/\/doi.org\/10.1016\/S1470-2045(24)00203-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1358_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12916-023-02866-y","volume":"21","author":"T Wu","year":"2023","unstructured":"Wu T, Zhang X, Liu X, Cai X, Shen T, Pan D, et al. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability. BMC Med. 2023;21(1):161.","journal-title":"BMC Med"},{"issue":"5","key":"1358_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.dld.2022.09.015","volume":"55","author":"S Barraud","year":"2023","unstructured":"Barraud S, Tougeron D, Villeneuve L, Eveno C, Bayle A, Parc Y, et al. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR\/MSI-H colorectal cancer, a BIG-RENAPE collaboration. Dig Liver Dis. 2023;55(5):673\u20138.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"1358_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJ Williams","year":"2024","unstructured":"Williams CJ, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21(12):839\u201351.","journal-title":"Nat Rev Clin Oncol"},{"issue":"06","key":"1358_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1055\/s-0043-1767703","volume":"36","author":"B Xiao","year":"2023","unstructured":"Xiao B, Yu J, Ding PR. Nonoperative management of dMMR\/MSI-H colorectal cancer following neoadjuvant immunotherapy: a narrative review. Clin Colon Rectal Surg. 2023;36(06):378\u201384.","journal-title":"Clin Colon Rectal Surg"},{"issue":"12","key":"1358_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/bjs\/znab342","volume":"108","author":"A Kanani","year":"2021","unstructured":"Kanani A, Veen T, S\u00f8reide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg. 2021;108(12):1417\u201325.","journal-title":"Br J Surg"},{"issue":"2","key":"1358_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ejso.2022.10.018","volume":"49","author":"L Cabez\u00f3n-Guti\u00e9rrez","year":"2023","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S, Palka-Kotlowska M, D\u00edaz-P\u00e9rez D, Mateos-Dominguez M, Galindo-Jara P. Neoadjuvant immunotherapy for dMMR\/MSI-H locally advanced rectal cancer: the future new standard approach? Eur J Surg Oncol. 2023;49(2):323\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"16","key":"1358_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540751","volume":"1","author":"HX Cui","year":"2025","unstructured":"Cui HX, Yang XQ, Zhao GY, Wang FJ, Liu X. The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review. Front Immunol. 2025;1(16):1540751.","journal-title":"Front Immunol"},{"issue":"9","key":"1358_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fonc.2019.00396","volume":"14","author":"AF Oliveira","year":"2019","unstructured":"Oliveira AF, Bretes L, Furtado I. Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer. Front Oncol. 2019;14(9):396.","journal-title":"Front Oncol"},{"issue":"12","key":"1358_CR28","volume":"26","author":"M Yang","year":"2021","unstructured":"Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, et al. Dual effects of cyclooxygenase inhibitors in combination with CD19. CAR-T cell immunotherapy Frontiers in immunology. 2021;26(12):670088.","journal-title":"CAR-T cell immunotherapy Frontiers in immunology"},{"issue":"15","key":"1358_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158726","volume":"23","author":"M Amato","year":"2022","unstructured":"Amato M, Franco R, Facchini G, Addeo R, Ciardiello F, Berretta M, et al. Microsatellite instability: from the implementation of the detection to a prognostic and predictive role in cancers. Int J Mol Sci. 2022;23(15):8726.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"1358_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153833","volume":"15","author":"M Ozer","year":"2023","unstructured":"Ozer M, Vegivinti CT, Syed M, Ferrell ME, Gonzalez Gomez C, Cheng S, et al. Neoadjuvant immunotherapy for patients with dMMR\/MSI-high gastrointestinal cancers: a changing paradigm. Cancers. 2023;15(15):3833.","journal-title":"Cancers"},{"issue":"10","key":"1358_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.intimp.2010.07.013","volume":"10","author":"MA I\u00f1iguez","year":"2010","unstructured":"I\u00f1iguez MA, Punz\u00f3n C, Cacheiro-Llaguno C, D\u00edaz-Mu\u00f1oz MD, Duque J, Cuberes R, et al. Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4, 5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors. Int Immunopharmacol. 2010;10(10):1295\u2013304.","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:41:43Z","timestamp":1764841303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01358-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"15 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this systematic review because it involved synthesizing data from previously published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"236"}}